Published in Pediatr Pulmonol on February 18, 2011
Myofibroblast differentiation and enhanced TGF-B signaling in cystic fibrosis lung disease. PLoS One (2013) 0.95
Tgf-β1 inhibits Cftr biogenesis and prevents functional rescue of ΔF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS One (2013) 0.90
Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. PLoS One (2013) 0.85
Decreased TGF-β1 and VEGF Release in Cystic Fibrosis Platelets: Further Evidence for Platelet Defects in Cystic Fibrosis. Lung (2016) 0.81
DNA and inflammatory mediators in bronchoalveolar lavage fluid from children with acute inhalational injuries. J Burn Care Res (2013) 0.81
Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. Ann Am Thorac Soc (2015) 0.81
Tgf-beta downregulation of distinct chloride channels in cystic fibrosis-affected epithelia. PLoS One (2014) 0.81
Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis. Mediators Inflamm (2013) 0.78
Transforming growth factor-β1 impairs CFTR-mediated anion secretion across cultured porcine vas deferens epithelial monolayer via the p38 MAPK pathway. Am J Physiol Cell Physiol (2013) 0.78
Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros (2013) 0.78
Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa. J Antimicrob Chemother (2012) 0.77
Using dendritic cells to evaluate how Burkholderia cenocepacia clonal isolates from a chronically infected cystic fibrosis patient subvert immune functions. Med Microbiol Immunol (2016) 0.76
Novel end points for clinical trials in young children with cystic fibrosis. Expert Rev Respir Med (2013) 0.75
Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline. Ann Am Thorac Soc (2016) 0.75
Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med (1999) 29.97
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol (2006) 9.53
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med (1994) 3.24
The role of transforming growth factor beta in lung development and disease. Chest (2004) 2.83
Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc (2006) 2.30
Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation (1998) 2.29
TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax (2000) 2.14
Disease-specific reference equations for lung function in patients with cystic fibrosis. Am J Respir Crit Care Med (2005) 2.13
Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med (1999) 2.08
Spirometric pulmonary function in healthy preschool children. Am J Respir Crit Care Med (2001) 1.96
Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest (2008) 1.57
Interactions between secondhand smoke and genes that affect cystic fibrosis lung disease. JAMA (2008) 1.51
Airway remodelling in children with cystic fibrosis. Thorax (2007) 1.38
Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin Chem (1997) 1.35
Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med (2008) 1.29
Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res (1995) 1.26
Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med (2003) 1.24
Development, repair and fibrosis: what is common and why it matters. Respirology (2009) 1.24
Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol (2003) 1.23
Advancing outcome measures for the new era of drug development in cystic fibrosis. Proc Am Thorac Soc (2007) 1.07
Transforming growth factor-beta (TGF-beta1) genotype and lung allograft fibrosis. J Heart Lung Transplant (1999) 1.03
Polymorphisms of TGF-beta1 in cystic fibrosis patients. Clin Immunol (2006) 1.01
Genetic variations in inflammatory mediators influence lung disease progression in cystic fibrosis. Pediatr Pulmonol (2008) 0.98
Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem (2005) 0.96
Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol (2006) 0.94
Transforming growth factor-beta(1) in bronchoalveolar lavage fluid from children with cystic fibrosis. Pediatr Pulmonol (2009) 0.92
Transforming growth factor beta in normal human lung: preferential location in bronchial epithelial cells. Thorax (1994) 0.90
A detailed protocol for the measurement of TGF-beta1 in human blood samples. J Immunol Methods (1997) 0.83
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med (2010) 6.23
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med (2005) 5.51
Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med (2006) 5.37
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell (2002) 4.94
Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med (2002) 4.75
Primary ciliary dyskinesia: diagnostic and phenotypic features. Am J Respir Crit Care Med (2003) 4.33
Congenital heart disease and other heterotaxic defects in a large cohort of patients with primary ciliary dyskinesia. Circulation (2007) 4.17
Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med (2008) 3.91
Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet (2011) 3.02
Genetic defects in ciliary structure and function. Annu Rev Physiol (2007) 2.94
DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects. Am J Respir Crit Care Med (2006) 2.92
Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol (2008) 2.84
Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome. Genet Med (2009) 2.71
A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol (2008) 2.58
Regulation of chloride channels by protein kinase C in normal and cystic fibrosis airway epithelia. Science (1989) 2.46
Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med (2002) 2.41
Mislocalization of DNAH5 and DNAH9 in respiratory cells from patients with primary ciliary dyskinesia. Am J Respir Crit Care Med (2005) 2.25
Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med (1997) 2.24
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat Genet (2012) 2.14
Deletions and point mutations of LRRC50 cause primary ciliary dyskinesia due to dynein arm defects. Am J Hum Genet (2009) 2.10
Evaluation metrics for biostatistical and epidemiological collaborations. Stat Med (2011) 2.09
Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease. Nature (2009) 2.05
Failure of cAMP agonists to activate rescued deltaF508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol (2005) 1.97
Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am J Respir Crit Care Med (2002) 1.94
Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator function. Am J Respir Crit Care Med (2013) 1.93
Zebrafish Ciliopathy Screen Plus Human Mutational Analysis Identifies C21orf59 and CCDC65 Defects as Causing Primary Ciliary Dyskinesia. Am J Hum Genet (2013) 1.90
Genetic modifiers of liver disease in cystic fibrosis. JAMA (2009) 1.88
Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation. Am J Respir Crit Care Med (2006) 1.80
What is cystic fibrosis? N Engl J Med (2002) 1.76
A bacterial cell to cell signal in the lungs of cystic fibrosis patients. FEMS Microbiol Lett (2002) 1.72
Review: Staphylococcus aureus and MRSA in cystic fibrosis. J Cyst Fibros (2011) 1.72
Physiologic, bronchoscopic, and bronchoalveolar lavage fluid findings in young children with recurrent wheeze and cough. Pediatr Pulmonol (2006) 1.65
Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol (2004) 1.64
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med (2008) 1.62
Endorectal repair of rectocele revisited. Br J Surg (1997) 1.57
Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis. Am J Respir Crit Care Med (2007) 1.55
The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis Rheum (2004) 1.54
Whole-exome capture and sequencing identifies HEATR2 mutation as a cause of primary ciliary dyskinesia. Am J Hum Genet (2012) 1.53
Fasting and postprandial markers of inflammation in lean and overweight children. Am J Clin Nutr (2009) 1.51
A(2) adenosine receptors regulate CFTR through PKA and PLA(2). Am J Physiol Lung Cell Mol Physiol (2002) 1.51
The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genet Med (2002) 1.49
Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. Ann Am Thorac Soc (2013) 1.49
Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. J Pediatr (2002) 1.44
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
DYX1C1 is required for axonemal dynein assembly and ciliary motility. Nat Genet (2013) 1.44
Next generation massively parallel sequencing of targeted exomes to identify genetic mutations in primary ciliary dyskinesia: implications for application to clinical testing. Genet Med (2011) 1.42
Disparities in lung transplantation before and after introduction of the lung allocation score. J Heart Lung Transplant (2013) 1.42
Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol (2007) 1.41
Cystic fibrosis transmembrane conductance regulator facilitates ATP release by stimulating a separate ATP release channel for autocrine control of cell volume regulation. J Biol Chem (2000) 1.40
Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. J Biol Chem (1999) 1.35
Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med (2003) 1.34
Activation of airway cl- secretion in human subjects by adenosine. Am J Respir Cell Mol Biol (2004) 1.32
Mutations in CCDC39 and CCDC40 are the major cause of primary ciliary dyskinesia with axonemal disorganization and absent inner dynein arms. Hum Mutat (2013) 1.31
Reduced expression of IRF7 in nasal epithelial cells from smokers after infection with influenza. Am J Respir Cell Mol Biol (2009) 1.29
Outcomes of critically ill children requiring continuous renal replacement therapy. J Crit Care (2009) 1.27
Strategies for developing biostatistics resources in an academic health center. Acad Med (2013) 1.27
Adiponectin is lower among African Americans and is independently related to insulin sensitivity in children and adolescents. Diabetes (2005) 1.27
High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol (2007) 1.26
Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet (2012) 1.26
Quantification of population structure using correlated SNPs by shrinkage principal components. Hum Hered (2010) 1.24
ZMYND10 is mutated in primary ciliary dyskinesia and interacts with LRRC6. Am J Hum Genet (2013) 1.24
Diagnostic yield of nasal scrape biopsies in primary ciliary dyskinesia: a multicenter experience. Pediatr Pulmonol (2011) 1.22
The presence of a matrix-derived neutrophil chemoattractant in bronchiolitis obliterans syndrome after lung transplantation. J Immunol (2009) 1.21
Primary ciliary dyskinesia: improving the diagnostic approach. Curr Opin Pediatr (2009) 1.21
ARMC4 mutations cause primary ciliary dyskinesia with randomization of left/right body asymmetry. Am J Hum Genet (2013) 1.17
Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity (Silver Spring) (2013) 1.17
The challenges of diagnosing primary ciliary dyskinesia. Proc Am Thorac Soc (2011) 1.16
DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther (2010) 1.16
Higher maternal gestational glucose concentration is associated with lower offspring insulin sensitivity and altered beta-cell function. J Clin Endocrinol Metab (2011) 1.14
Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry. J Biol Chem (2003) 1.12
Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. Am J Respir Crit Care Med (2015) 1.09
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol (2007) 1.08
SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol (2005) 1.08
Identification and analysis of axonemal dynein light chain 1 in primary ciliary dyskinesia patients. Am J Respir Cell Mol Biol (2005) 1.08
Activation of the cystic fibrosis transmembrane conductance regulator by the flavonoid quercetin: potential use as a biomarker of ΔF508 cystic fibrosis transmembrane conductance regulator rescue. Am J Respir Cell Mol Biol (2009) 1.07
Genetic and reproductive knowledge among adolescents and adults with cystic fibrosis. Chest (2008) 1.07
Different expression ratio of S100A8/A9 and S100A12 in acute and chronic lung diseases. Respir Med (2007) 1.06
Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis. Pediatr Pulmonol (2009) 1.06
Investigation of the possible role of a novel gene, DPCD, in primary ciliary dyskinesia. Am J Respir Cell Mol Biol (2003) 1.05
Racial variation in willingness to trade financial resources for life-prolonging cancer treatment. Cancer (2011) 1.04
Nasal lavage natural killer cell function is suppressed in smokers after live attenuated influenza virus. Respir Res (2011) 1.04
A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther (2001) 1.04
Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion (2007) 1.02
Matrix metalloproteinase activity in pediatric acute lung injury. Int J Med Sci (2008) 1.01
Burkholderia gladioli: five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros (2006) 1.01
Quantitative cytokine gene expression in CF airway. Pediatr Pulmonol (2004) 1.01
Basic protocol for transepithelial nasal potential difference measurements. J Cyst Fibros (2004) 1.01
Difference in dietary intake between women with polycystic ovary syndrome and healthy controls. Fertil Steril (2006) 1.00
The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium. Exp Lung Res (2004) 1.00
A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. Pediatr Pulmonol (2011) 1.00
Genetic causes of bronchiectasis: primary ciliary dyskinesia. Respiration (2007) 0.99
IL1B polymorphisms modulate cystic fibrosis lung disease. Pediatr Pulmonol (2009) 0.98
Effect of female partner age on pregnancy rates after vasectomy reversal. Fertil Steril (2007) 0.97
Effect of diet with and without exercise training on markers of inflammation and fat distribution in overweight women. Obesity (Silver Spring) (2010) 0.96
Genetic modifiers of cystic fibrosis-related diabetes. Diabetes (2013) 0.96